12 Month Price Forecast For LENZ
Distance to LENZ Price Forecasts
LENZ Price Momentum
๐ค Considering LENZ Therapeutics (LENZ)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 6, 2025 5:40 PM UTC
LENZ Analyst Ratings & Price Targets
Based on our analysis of 6 Wall Street analysts, LENZ has a consensus that is bullish. The median price target is $38.00, with forecasts ranging from $36.00 to $45.00. Currently, there are 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With LENZ currently trading at $26.79, the median price forecast suggests a 41.8% upside. The most optimistic forecast comes from at , projecting a 68.0% upside, while Joseph Catanzaro at Piper Sandler provides the most conservative target, suggesting a 34.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LENZ Analyst Consensus
LENZ Price Target Range
Latest LENZ Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LENZ.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Nov 7, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $38.00 |
Sep 27, 2024 | Raymond James | Gary Nachman | Outperform | Initiates | $37.00 |
Aug 15, 2024 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $36.00 |
Aug 15, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $38.00 |
Aug 12, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Initiates | $38.00 |
Apr 15, 2024 | Leerink Partners | Marc Goodman | Outperform | Initiates | $32.00 |
Apr 15, 2024 | William Blair | Tim Lugo | Outperform | Initiates | $0.00 |
Apr 10, 2024 | Citigroup | Yigal Nochomovitz | Buy | Initiates | $34.00 |
Mar 27, 2024 | Piper Sandler | Joseph Catanzaro | Overweight | Initiates | $28.00 |
Stocks Similar to LENZ Therapeutics, Inc.
The following stocks are similar to LENZ Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

LENZ Therapeutics, Inc. (LENZ) Financial Data
LENZ Therapeutics, Inc. has a market capitalization of $736.75M with a P/E ratio of -9.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -41.9%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

LENZ Therapeutics, Inc. (LENZ) Company Overview
About LENZ Therapeutics, Inc.
Develops therapies to improve vision.
LENZ Therapeutics operates as a biopharmaceutical company focused on developing therapies for vision improvement. The company generates revenue through the commercialization of its product candidates, which are currently in Phase III clinical trials, indicating a strong potential for market entry and sales.
Based in Del Mar, California, LENZ Therapeutics is working on innovative solutions for presbyopia, a common age-related vision condition, which could position the company favorably in the growing eye care market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
0
CEO
Mr. Evert B. Schimmelpennink
Country
United States
IPO Year
2024
Website
www.lenz-tx.comLENZ Therapeutics, Inc. (LENZ) Latest News & Analysis
LENZ Therapeutics (LENZ) has formed a hammer chart pattern, suggesting support for the stock. This, along with rising earnings estimate revisions, may indicate a potential trend reversal.
A hammer chart pattern suggests LENZ has found support, signaling potential price reversal, while rising earnings estimates indicate improving fundamentals, making it a stock to watch.
LENZ Therapeutics (Nasdaq: LENZ) will participate in upcoming investor conferences as it develops a unique aceclidine-based eye drop for presbyopia.
LENZ Therapeutics' participation in investor conferences signals potential growth and interest in its innovative eye drop, which could attract investment and affect stock performance.
LENZ Therapeutics, Inc. (NASDAQ:LENZ) will host its Q3 2024 earnings conference call on November 6, 2024, at 8:30 AM ET, featuring key company executives and analysts.
The earnings conference call will provide insights into LENZ Therapeutics' financial performance and strategic direction, influencing investor sentiment and potential stock movements.
Corxel Pharmaceuticals and LENZ Therapeutics announced topline results from the Phase 3 JX07001 trial of LNZ100 for presbyopia in China.
Topline data from a Phase 3 trial can significantly impact stock prices for Corxel Pharmaceuticals and LENZ Therapeutics, indicating potential market success or setbacks for their treatments.
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100
3 months agoLNZ100 met its primary endpoint, with 74% of participants showing significant improvement in visual acuity at 3 hours post-treatment compared to the vehicle group.
The positive efficacy results for LNZ100 suggest strong market potential, likely boosting investor confidence and interest in the companyโs stock and future profitability.
Frequently Asked Questions About LENZ Stock
What is LENZ Therapeutics, Inc.'s (LENZ) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, LENZ Therapeutics, Inc. (LENZ) has a median price target of $38.00. The highest price target is $45.00 and the lowest is $36.00.
Is LENZ stock a good investment in 2025?
According to current analyst ratings, LENZ has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $26.79. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for LENZ stock?
Wall Street analysts predict LENZ stock could reach $38.00 in the next 12 months. This represents a 41.8% increase from the current price of $26.79. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is LENZ Therapeutics, Inc.'s business model?
LENZ Therapeutics operates as a biopharmaceutical company focused on developing therapies for vision improvement. The company generates revenue through the commercialization of its product candidates, which are currently in Phase III clinical trials, indicating a strong potential for market entry and sales.
What is the highest forecasted price for LENZ LENZ Therapeutics, Inc.?
The highest price target for LENZ is $45.00 from at , which represents a 68.0% increase from the current price of $26.79.
What is the lowest forecasted price for LENZ LENZ Therapeutics, Inc.?
The lowest price target for LENZ is $36.00 from Joseph Catanzaro at Piper Sandler, which represents a 34.4% increase from the current price of $26.79.
What is the overall LENZ consensus from analysts for LENZ Therapeutics, Inc.?
The overall analyst consensus for LENZ is bullish. Out of 6 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $38.00.
How accurate are LENZ stock price projections?
Stock price projections, including those for LENZ Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.